EpiHeart is a young medical device company focused on enabling Cardiac Micrograft Therapy™, an adjuvant therapy administered during cardiac interventions such as coronary artery bypass grafting surgery. Cardiac Micrograft Therapy™ is a novel therapy for treating ischemic injury and consequent ischemic scars and heart failures. The company is focused on the development and commercialization of medical device packages to enable the therapy and it aims to drive the therapy into mainstream clinical use. The first-in-man clinical trial has already been completed in academic setting. The company is a spin-out from the University of Helsinki and the HUS Helsinki University Hospital.

    • Founding year: 

    • Development phase:
Early clinical stage

    • Funding stage:

    • Website: 

    • Contact person info: 

    • Team members: 

    • Article:
Read an article about EpiHeart.